A randomized, double-blind, placebo-controlled crossover clinical trial to evaluate the anti-diabetic effects of Allium hookeri extract in the subjects with prediabetes

Allium hookeri is widely consumed as a vegetable and herbal medicine in Asia. A. hookeri has been reported anti-inflammatory, anti-obesity, osteoblastic, anti-oxidant, and anti-diabetic effects in animal studies. We investigated the anti-diabetic effects of A. hookeri aqueous extract (AHE) in the Ko...

Full description

Saved in:
Bibliographic Details
Published inBMC complementary and alternative medicine Vol. 20; no. 1; p. 211
Main Authors Park, Soo-Hyun, Bae, Ui-Jin, Choi, Eun-Kyung, Jung, Su-Jin, Lee, Sung-Hyen, Yang, Jae-Heon, Kim, You-Suk, Jeong, Do-Youn, Kim, Hyun-Ju, Park, Byung-Hyun, Chae, Soo-Wan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 06.07.2020
BioMed Central
BMC
Subjects
Online AccessGet full text
ISSN2662-7671
2662-7671
1472-6882
DOI10.1186/s12906-020-03005-3

Cover

Loading…
More Information
Summary:Allium hookeri is widely consumed as a vegetable and herbal medicine in Asia. A. hookeri has been reported anti-inflammatory, anti-obesity, osteoblastic, anti-oxidant, and anti-diabetic effects in animal studies. We investigated the anti-diabetic effects of A. hookeri aqueous extract (AHE) in the Korean subjects. Prediabetic subjects (100 ≤ fasting plasma glucose (FPG) < 126 mg/dL) who met the inclusion criteria were recruited for this study. The enrolled subjects (n = 30) were randomly divided into either an AHE (n = 15, 486 mg/day) or placebo (n = 15) group. Outcomes were measurements of FPG, glycemic response to an oral glucose tolerance test (OGTT), insulin, C-peptide, hemoglobin A1c (HbA1c), total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol. The t-test was used to assess differences between the groups. A p-value < 0.05 was considered statistically significant. Eight weeks after AHE supplementation, HbA1c level was significantly decreased in the AHE group compared with the placebo group. No clinically significant changes in any safety parameter were observed. The findings suggest that AHE can be effective in reducing HbA1c, indicating it as an adjunctive tool for improving glycemic control. The study protocol was retrospectively registered at www.clinicaltrials.gov ( NCT03330366 , October 30, 2017).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:2662-7671
2662-7671
1472-6882
DOI:10.1186/s12906-020-03005-3